Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

SCAI Releases Practical, Technical Advice for Primary PCI in STEMI

Michael O'Riordan

October 10, 2024

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

News Daily News

Greater Carotid Plaque Burden in Asthmatic Patients: MESA

Michael O'Riordan

November 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

FDA Proposes Ban on Menthol Cigarettes and Flavored Cigars

Michael O'Riordan

April 28, 2022

News Conference News EuroPCR 2021

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

Michael O'Riordan

May 21, 2021

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Daily News

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

Michael O'Riordan

January 15, 2019

News Daily News

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Michael O'Riordan

October 17, 2018

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Run to Your Heart’s Content: Marathons Not Linked With Subclinical Atherosclerosis

Michael O'Riordan

June 09, 2017

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Daily News

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Michael O'Riordan

September 29, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Potential Genetic Link Between Platelet Activity and Cardiovascular Disease Identified

Michael O'Riordan

September 22, 2016

News Daily News

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Michael O'Riordan

September 22, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Conference News ESC 2016

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

Michael O'Riordan

August 31, 2016

Advertisement

What’s Going to Be Hot at TCT 2025

SCAI Releases Practical, Technical Advice for Primary PCI in STEMI

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Greater Carotid Plaque Burden in Asthmatic Patients: MESA

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

FDA Proposes Ban on Menthol Cigarettes and Flavored Cigars

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Run to Your Heart’s Content: Marathons Not Linked With Subclinical Atherosclerosis

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Potential Genetic Link Between Platelet Activity and Cardiovascular Disease Identified

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content